2022
DOI: 10.29011/2574-7568.010104
|View full text |Cite
|
Sign up to set email alerts
|

A Randomized, Double-blind, Active-controlled Study of Remogliflozin Etabonate 100 mg plus Teneligliptin 10 mg Twice-daily versus Teneligliptin 20 mg Oncedaily as add-on to Metformin Monotherapy in Indian Diabetic Patients

Abstract: Background: Fixed-dose combination (FDC) of sodium-glucose co-transporter-2 inhibitor (SGLT2i) and dipeptidyl peptidase-4 inhibitor (DPP4i) is a promising approach for type 2 diabetes (T2D) management due to their complementary mode of action. The present study evaluated efficacy and safety of FDC of remogliflozin etabonate (RE) and teneligliptin as add-on to metformin monotherapy in uncontrolled T2D patients compared to standard teneligliptin therapy. Methods: This 16-week, double-blind, double-dummy, active-… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 23 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?